The company also announced that more than 500 patients have ingested PillCam Colon 2 in the trial.
The PillCam Colon 2 video capsule is equipped with two miniature color video cameras (one on each end), a battery and an LED light source.
In order to record the colon, PillCam Colon 2 is ingested by the patient which transmit up to 35 frames per second for approximately 10 hours.
The device data is transferred to a computer that uses RAPID software to compile the video data, which aids physicians to review and report the results of the PillCam study.
Given Imaging president and CEO Homi Shamir said they are pleased with their progress enrolling patients in the PillCam COLON 2 pivotal trial and they are on track to complete the enrollment phase of the trial in the May/June timeframe.
Given Imaging said the results will support the company’s 510k submission to the US
Food and Drug Administration (FDA).
